A Phase III Open Label, Multi-Center Pediatric Study in China Comparing Booster Doses of Vaxem Hib and Hiberix Vaccines for the Prevention of Haemophilus Influenzae Type b (Hib) Infection.

Trial Profile

A Phase III Open Label, Multi-Center Pediatric Study in China Comparing Booster Doses of Vaxem Hib and Hiberix Vaccines for the Prevention of Haemophilus Influenzae Type b (Hib) Infection.

Completed
Phase of Trial: Phase III

Latest Information Update: 14 Jun 2013

At a glance

  • Drugs TAK 816 (Primary) ; Hib vaccine conjugate
  • Indications Haemophilus infections
  • Focus Adverse reactions; Pharmacodynamics; Registrational
  • Sponsors Novartis
  • Most Recent Events

    • 29 Jul 2010 Actual end date (Apr 2010) added as reported by ClinicalTrials.gov (NCT01025544).
    • 29 Jul 2010 Actual end date (Apr 2010) added as reported by ClinicalTrials.gov (NCT01025544).
    • 02 Dec 2009 Booster trial identified and integrated (NCT01025544).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top